Joel Beatty
Stock Analyst at Baird
(4.14)
# 449
Out of 4,884 analysts
202
Total ratings
41.1%
Success rate
17.31%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Neutral | $7 → $9 | $9.08 | -0.88% | 5 | Jun 20, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $129.48 | +11.99% | 6 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $21.24 | +45.95% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $19.75 | +21.52% | 3 | May 16, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $2.56 | +56.25% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $18.40 | +171.74% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $545.11 | +24.75% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $14.90 | +94.63% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $49.15 | +34.28% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $109.92 | +41.01% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $7.41 | -5.53% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $103.91 | +55.90% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $29.00 | +41.38% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.11 | +221.54% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $7.08 | +125.99% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $3.98 | +302.52% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $46.32 | +57.60% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $21.45 | +49.18% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $28.01 | +167.76% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $6.57 | +67.43% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.70 | +311.76% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $57.17 | +13.70% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $128.20 | -0.94% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $39.46 | +82.46% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.23 | +8,450.66% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.40 | +221.43% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $12.44 | +100.96% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.29 | +3,025.00% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $9.00 | +211.11% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.36 | +577.97% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.30 | -45.65% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.20 | +3,566.67% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $16.90 | +243.20% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $21.93 | +9.44% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $13.62 | +32.16% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.59 | +67.13% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.32 | +2,248.48% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.43 | +415.65% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $329.77 | -46.93% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.89 | +186.30% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $18.20 | +493.57% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $43.59 | +78.94% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $10.42 | +859.69% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.60 | +622.89% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $1.98 | +22,627.27% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.15 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.76 | +121.89% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.58 | +20,568.27% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $5.81 | +227.02% | 3 | Nov 10, 2017 |
Sage Therapeutics
Jun 20, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $9.08
Upside: -0.88%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $129.48
Upside: +11.99%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $21.24
Upside: +45.95%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $19.75
Upside: +21.52%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $2.56
Upside: +56.25%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $18.40
Upside: +171.74%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $545.11
Upside: +24.75%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $14.90
Upside: +94.63%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $49.15
Upside: +34.28%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $109.92
Upside: +41.01%
May 7, 2025
Maintains: Neutral
Price Target: $8 → $7
Current: $7.41
Upside: -5.53%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $103.91
Upside: +55.90%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $29.00
Upside: +41.38%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.11
Upside: +221.54%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $7.08
Upside: +125.99%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $3.98
Upside: +302.52%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $46.32
Upside: +57.60%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $21.45
Upside: +49.18%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $28.01
Upside: +167.76%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $6.57
Upside: +67.43%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.70
Upside: +311.76%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $57.17
Upside: +13.70%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $128.20
Upside: -0.94%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $39.46
Upside: +82.46%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.23
Upside: +8,450.66%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.40
Upside: +221.43%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $12.44
Upside: +100.96%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.29
Upside: +3,025.00%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $9.00
Upside: +211.11%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.36
Upside: +577.97%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.30
Upside: -45.65%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.20
Upside: +3,566.67%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $16.90
Upside: +243.20%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $21.93
Upside: +9.44%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $13.62
Upside: +32.16%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.59
Upside: +67.13%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.32
Upside: +2,248.48%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.43
Upside: +415.65%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $329.77
Upside: -46.93%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.89
Upside: +186.30%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $18.20
Upside: +493.57%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $43.59
Upside: +78.94%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $10.42
Upside: +859.69%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.60
Upside: +622.89%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $1.98
Upside: +22,627.27%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.15
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.76
Upside: +121.89%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.58
Upside: +20,568.27%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $5.81
Upside: +227.02%